
Brenetafusp shows 87% 6-month survival in advanced melanoma, advancing Phase 3 trial plans.
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and...



